secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001437749-23-016029
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica appoints former Medtronic CMO Richard Kuntz to Board of Directors
---------------------------------------------------------------------------

- Dr. Kuntz appointed effective May 30, 2023; he recently retired as Medtronic's Chief Medical and Scientific Officer.
- He received an option to purchase 32,320 voting common shares at fair market value, vesting quarterly over 3 years.
- Kuntz will receive standard non-employee director compensation and a standard indemnification agreement.
- His expertise in stroke and clinical trial design aligns with DiaMedica's ReMEDy2 acute ischemic stroke trial.
- Kuntz founded the Harvard Clinical Research Institute and served on boards of ZimVie and Identiv.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923016029/0001437749-23-016029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923016029/dmtp20230529_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-016029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer